 EVANSTON, Ill.--BUSINESS WIRE--Aptinyx Inc. Nasdaq: APTX, a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that it has finalized the design of its Phase 2b program for NYX-783 in patients with post-traumatic stress disorder PTSD after having received the minutes from its recent Type C meeting with the U.S. Food and Drug Administration FDA. The company expects to initiate the Phase 2b program in 